IGM Biosciences, Inc.
IGMS
$1.22
$0.032.52%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.68M | 2.92M | 2.91M | 2.11M | 2.13M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.68M | 2.92M | 2.91M | 2.11M | 2.13M |
| Cost of Revenue | 155.19M | 184.38M | 193.00M | 206.71M | 213.79M |
| Gross Profit | -152.51M | -181.46M | -190.09M | -204.61M | -211.66M |
| SG&A Expenses | 41.71M | 51.43M | 45.18M | 47.51M | 49.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 196.90M | 235.81M | 238.18M | 254.22M | 263.77M |
| Operating Income | -194.22M | -232.89M | -235.27M | -252.12M | -261.64M |
| Income Before Tax | -195.80M | -219.60M | -219.92M | -236.33M | -245.74M |
| Income Tax Expenses | -- | 242.00K | 482.00K | 591.00K | 678.00K |
| Earnings from Continuing Operations | -195.80 | -219.84 | -220.40 | -236.92 | -246.42 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -195.80M | -219.84M | -220.40M | -236.92M | -246.42M |
| EBIT | -194.22M | -232.89M | -235.27M | -252.12M | -261.64M |
| EBITDA | -185.11M | -223.95M | -226.37M | -243.33M | -253.36M |
| EPS Basic | -3.24 | -3.65 | -3.68 | -4.31 | -4.82 |
| Normalized Basic EPS | -1.95 | -2.28 | -2.29 | -2.69 | -3.04 |
| EPS Diluted | -3.24 | -3.65 | -3.68 | -4.31 | -4.82 |
| Normalized Diluted EPS | -1.95 | -2.28 | -2.29 | -2.69 | -3.04 |
| Average Basic Shares Outstanding | 242.06M | 241.04M | 239.96M | 224.65M | 209.00M |
| Average Diluted Shares Outstanding | 242.06M | 241.04M | 239.96M | 224.65M | 209.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |